Teleflex Q3: Revenue Flat at $567.8M, Gross Margin Jumps to 65.0%, OEM Sale Drives $927.4M Net Income
TFX sits 53% above its 52-week low of $100.18.
Summary
Teleflex's Q3 revenue was flat at $567.8 million, but gross margin rose to 65.0% and continuing operations earned $1.30 per diluted share; net income of $927.4 million was driven by the $1.0 billion pre-tax gain on the completed OEM sale, whose proceeds cut gross debt to $1.63 billion.
Key Events · Earnings and Guidance · TFX
-
Q3 Revenue Flat, Margins Expand
Net revenues were $567.8 million, up 0.2% from $566.9 million, while gross margin rose to 65.0% from 51.5% on the non-recurrence of BIOTRONIK inventory step-up charges and a $25.3 million IEEPA tariff refund.
-
Continuing Ops Earn $1.30 Per Share
Income from continuing operations was $54.3 million, or $1.30 diluted, versus a $58.4 million loss a year ago; net income of $927.4 million included $873.1 million from discontinued operations.
-
OEM Sale Closes, Debt Cut Sharply
The OEM divestiture closed August 3, 2026 with $1.5 billion net proceeds ($1.3 billion after tax) and a $1.0 billion pre-tax gain; gross borrowings fell to $1.63 billion from $2.65 billion after paying off the $700 million term A-2 loan and $490 million of the revolver.
-
Interventional Goodwill Cushion Thin
The Interventional reporting unit's fair value exceeds carrying value by only about 15%; a hypothetical 1% increase in the discount rate would reduce that excess to less than 5%, leaving impairment risk.
Analysis · TFX · Industrial Applications And Services
The headline numbers were already out this morning, but the 10-Q is where the quality of the quarter shows. Revenue was essentially flat at $567.8 million, up 0.2%, so the 39% adjusted EPS growth came from margin and below-the-line items rather than volume: gross margin jumped to 65.0% from 51.5%, helped by the absence of last year's BIOTRONIK inventory step-up charge and a $25.3 million IEEPA tariff refund. Continuing operations earned $54.3 million, or $1.30 per diluted share, versus a loss a year ago. The $927.4 million of net income is mostly accounting: $873.1 million came from discontinued operations, including a $1.0 billion pre-tax gain on the OEM sale that closed August 3. Cash generation improved sharply, with $234.8 million from continuing operations versus $10.3 million, and the company used the $1.5 billion of OEM proceeds to cut gross debt to $1.63 billion from $2.65 billion. Two things deserve attention: the Interventional reporting unit's fair value is only about 15% above carrying value, so a 1% higher discount rate would leave less than 5% of cushion and put goodwill at risk; and the company added a new risk factor on Irenic Capital's activist campaign, which keeps governance and portfolio strategy in play. The remaining Acute Care and IU sale, expected to bring roughly $530 million, is still targeted for end-2026 but could slip into 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TFX was trading at $153.36 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $100.18 to $156.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.